HERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.45 USD | -3.92% |
|
-7.20% | +44.12% |
| Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
| Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,116 | 1,923 | 930.7 | 297.2 | 255.1 | 368.4 | - | - |
| Enterprise Value (EV) 1 | 2,116 | 1,923 | 930.7 | 297.2 | 255.1 | 368.4 | 368.4 | 368.4 |
| P/E ratio | -9.4 x | -8.47 x | -4.08 x | -1.5 x | -2.13 x | -11.5 x | -38.7 x | 13.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 14.5 x | 21.7 x | 10.8 x | 2.76 x | 2.01 x | 2.54 x | 2.1 x | 1.73 x |
| EV / Revenue | 14.5 x | 21.7 x | 10.8 x | 2.76 x | 2.01 x | 2.54 x | 2.1 x | 1.73 x |
| EV / EBITDA | - | -8,534,465 x | - | - | - | - | - | - |
| EV / FCF | -16.1 x | -10 x | -4.51 x | -2 x | - | -11.2 x | -19.1 x | 15.6 x |
| FCF Yield | -6.22% | -9.97% | -22.2% | -50% | - | -8.9% | -5.23% | 6.39% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 90,051 | 90,855 | 101,935 | 118,888 | 150,073 | 150,363 | - | - |
| Reference price 2 | 23.50 | 21.16 | 9.130 | 2.500 | 1.700 | 2.450 | 2.450 | 2.450 |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 146 | 88.64 | 86.35 | 107.7 | 127 | 144.9 | 175.2 | 212.8 |
| EBITDA | - | -225.3 | - | - | - | - | - | - |
| EBIT 1 | -210.7 | -228.2 | -217.8 | -174.7 | -110.6 | -32.47 | -9.783 | 28.7 |
| Operating Margin | -144.34% | -257.41% | -252.27% | -162.21% | -87.07% | -22.41% | -5.59% | 13.48% |
| Earnings before Tax (EBT) 1 | -204.7 | -227.3 | -220.7 | -182 | -110.6 | -32.32 | -9.917 | 29.7 |
| Net income 1 | -204.7 | -227.3 | -220.7 | -182 | -110.6 | -32.32 | -9.917 | 29.7 |
| Net margin | -140.27% | -256.41% | -255.58% | -169.05% | -87.02% | -22.31% | -5.66% | 13.95% |
| EPS 2 | -2.500 | -2.500 | -2.240 | -1.670 | -0.8000 | -0.2133 | -0.0633 | 0.1850 |
| Free Cash Flow 1 | -131.7 | -191.6 | -206.4 | -148.7 | - | -32.8 | -19.25 | 23.55 |
| FCF margin | -90.25% | -216.2% | -239.01% | -138.14% | - | -22.64% | -10.99% | 11.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 79.29% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.23 | 20.66 | 23.46 | 27.63 | 26.56 | 30.03 | 29.62 | 31.76 | 31.43 | 34.23 | 32.98 | 34.52 | 36.95 | 40.48 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.71 | -53.54 | -62.92 | -49.5 | -41.88 | -20.36 | -33.06 | -42.4 | -24.93 | -10.22 | -10.87 | -8.833 | -7.833 | -4.933 |
| Operating Margin | -222.59% | -259.2% | -268.25% | -179.15% | -157.71% | -67.79% | -111.64% | -133.5% | -79.31% | -29.85% | -32.95% | -25.59% | -21.2% | -12.19% |
| Earnings before Tax (EBT) 1 | -52.41 | -54.65 | -63.89 | -56.36 | -41.91 | -19.87 | -32.77 | -42.06 | -25.01 | -10.72 | -10.66 | -8.745 | -7.817 | -5.058 |
| Net income 1 | -52.41 | -54.65 | -63.89 | -56.36 | -41.91 | -19.87 | -32.77 | -42.06 | -25.01 | -10.72 | -10.66 | -8.745 | -7.817 | -5.058 |
| Net margin | -225.6% | -264.57% | -272.36% | -203.98% | -157.8% | -66.17% | -110.65% | -132.42% | -79.56% | -31.33% | -32.33% | -25.33% | -21.15% | -12.5% |
| EPS 2 | -0.5100 | -0.5400 | -0.6300 | -0.5500 | -0.3800 | -0.1700 | -0.2700 | -0.3500 | -0.1700 | -0.0700 | -0.0700 | -0.0567 | -0.0500 | -0.0333 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/28/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/23/23 | 5/11/23 | 8/14/23 | 11/14/23 | 3/12/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -132 | -192 | -206 | -149 | - | -32.8 | -19.3 | 23.6 |
| ROE (net income / shareholders' equity) | -52.9% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | -1.520 | - | - | - | - | - | - | - |
| Capex 1 | 7.15 | 6.81 | 3.02 | 1.83 | - | 3 | 2.3 | 2.3 |
| Capex / Sales | 4.9% | 7.69% | 3.5% | 1.69% | - | 2.07% | 1.31% | 1.08% |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.45
USD
Average target price
6.75
USD
Spread / Average Target
+175.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.12% | 368M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- HRTX Stock
- Financials Heron Therapeutics, Inc.
